MA25658A1 - Sels hydrochlores de 5(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thyazolidine-2,4-dione. - Google Patents

Sels hydrochlores de 5(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thyazolidine-2,4-dione.

Info

Publication number
MA25658A1
MA25658A1 MA26814A MA26814A MA25658A1 MA 25658 A1 MA25658 A1 MA 25658A1 MA 26814 A MA26814 A MA 26814A MA 26814 A MA26814 A MA 26814A MA 25658 A1 MA25658 A1 MA 25658A1
Authority
MA
Morocco
Prior art keywords
thyazolidine
hydrochlorine
pyridil
dione
ethoxy
Prior art date
Application number
MA26814A
Other languages
English (en)
Inventor
Andrew Simon Craig
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA25658A1 publication Critical patent/MA25658A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA26814A 2000-03-14 2002-09-12 Sels hydrochlores de 5(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thyazolidine-2,4-dione. MA25658A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0006133.3A GB0006133D0 (en) 2000-03-14 2000-03-14 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
MA25658A1 true MA25658A1 (fr) 2002-12-31

Family

ID=9887600

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26814A MA25658A1 (fr) 2000-03-14 2002-09-12 Sels hydrochlores de 5(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thyazolidine-2,4-dione.

Country Status (31)

Country Link
US (2) US7074811B2 (fr)
EP (1) EP1265893B1 (fr)
JP (1) JP2003527393A (fr)
KR (1) KR100746813B1 (fr)
CN (1) CN100516062C (fr)
AP (1) AP1545A (fr)
AT (1) ATE302202T1 (fr)
AU (1) AU777987B2 (fr)
BG (1) BG65924B1 (fr)
BR (1) BR0108870A (fr)
CA (1) CA2403109A1 (fr)
CZ (1) CZ20023074A3 (fr)
DE (1) DE60112729T2 (fr)
DK (1) DK1265893T3 (fr)
DZ (1) DZ3316A1 (fr)
EA (1) EA005115B1 (fr)
ES (1) ES2243458T3 (fr)
GB (1) GB0006133D0 (fr)
HK (1) HK1052502A1 (fr)
HU (1) HUP0300158A3 (fr)
IL (2) IL151425A0 (fr)
MA (1) MA25658A1 (fr)
MX (1) MXPA02008972A (fr)
NO (1) NO323448B1 (fr)
NZ (1) NZ520910A (fr)
OA (1) OA12229A (fr)
PL (1) PL357283A1 (fr)
SK (1) SK286399B6 (fr)
UA (1) UA73974C2 (fr)
WO (1) WO2001068646A1 (fr)
ZA (1) ZA200207292B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
DE60217168T2 (de) * 2001-11-21 2007-10-04 Smithkline Beecham Plc, Brentford 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dion-benzolsulfonat; prozess zu seiner herstellung; polymorphe i, ii und iii davon; und seine verwendung als pharmazeutischer wirkstoff
WO2003050112A1 (fr) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Hydrates de toluenesulfonate d'un derive de thiazolidinedione
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006018853A2 (fr) 2004-08-19 2006-02-23 Hetero Drugs Limited Nouveaux polymorphes d'efavirenz
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011138421A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combinaison thérapeutique
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (fr) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2015128453A1 (fr) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Utilisation médicale d'un inhibiteur de dpp-4
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US137940A (en) * 1873-04-15 Improvement in elevators
US120078A (en) * 1871-10-17 Improvement in revolving flower-stands
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
EP0842925A1 (fr) 1987-09-04 1998-05-20 Beecham Group Plc Thiazolidinédiones substituées
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5708012A (en) 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
AU8539398A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9909075D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
OA11871A (en) 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
PE20010045A1 (es) 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidin-2,4-diona
ES2203453T3 (es) 1999-04-23 2004-04-16 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bentil)tiazolidina-2,4-diona.
HU225919B1 (en) 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
CN1277965A (zh) 2000-06-14 2000-12-27 中国医药研究开发中心 盐酸罗格列酮及其应用
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical

Also Published As

Publication number Publication date
DE60112729T2 (de) 2006-06-08
BR0108870A (pt) 2002-12-17
SK13302002A3 (sk) 2003-02-04
ES2243458T3 (es) 2005-12-01
ZA200207292B (en) 2003-05-06
PL357283A1 (en) 2004-07-26
HUP0300158A3 (en) 2005-04-28
US20050267162A1 (en) 2005-12-01
CN1358184A (zh) 2002-07-10
EP1265893B1 (fr) 2005-08-17
BG65924B1 (bg) 2010-05-31
NZ520910A (en) 2004-06-25
NO323448B1 (no) 2007-05-07
HUP0300158A2 (en) 2003-05-28
MXPA02008972A (es) 2003-02-10
UA73974C2 (en) 2005-10-17
AU4084301A (en) 2001-09-24
CN100516062C (zh) 2009-07-22
CA2403109A1 (fr) 2001-09-20
ATE302202T1 (de) 2005-09-15
NO20024307L (no) 2002-09-09
NO20024307D0 (no) 2002-09-09
DZ3316A1 (fr) 2001-09-20
KR100746813B1 (ko) 2007-08-06
AP2002002600A0 (en) 2002-09-30
OA12229A (en) 2003-11-07
AP1545A (en) 2006-01-12
DK1265893T3 (da) 2005-11-14
US20040152901A1 (en) 2004-08-05
HK1052502A1 (en) 2003-09-19
JP2003527393A (ja) 2003-09-16
GB0006133D0 (en) 2000-05-03
DE60112729D1 (de) 2005-09-22
BG107012A (bg) 2003-04-30
EA005115B1 (ru) 2004-10-28
SK286399B6 (sk) 2008-09-05
CZ20023074A3 (cs) 2003-02-12
EA200200975A1 (ru) 2003-02-27
KR20020079998A (ko) 2002-10-21
US7074811B2 (en) 2006-07-11
WO2001068646A1 (fr) 2001-09-20
IL151425A (en) 2009-08-03
EP1265893A1 (fr) 2002-12-18
IL151425A0 (en) 2003-04-10
AU777987B2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
MA25658A1 (fr) Sels hydrochlores de 5(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thyazolidine-2,4-dione.
EE200300196A (et) Spiropürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
DE60004196D1 (de) Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz
AP2000001831A0 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin e-2,4-dione maleic acid salt hydrate as pharmaceutical
DZ3475A1 (fr) Le sels hydrochloridrates de 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
DZ3480A1 (fr) Sels de sodium de 5-'4-'2-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidine-2,4-dione
AU2002352386A1 (en) Hydrogensulfate salt of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thia zolidine-2,4-dione
AU6255001A (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
AU2002222305A1 (en) 5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
SI1265893T1 (sl) Hidrokloridne soli 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil)tiazolidin-2,4-diona
HK1061392A1 (en) 5-'4-'2-(N-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione mesylate salt
IT1318483B1 (it) Dispositivo per la chiusura di un capo di abbigliamento o simile, adelevata praticita' di impiego.
PT102339A (pt) Sal hidrocloreto de um derivado de tiazolidinodiona substituido